Ligand Pharmaceuticals Incorporated (FRA:LGDN)
Germany · Delayed Price · Currency is EUR | Market Cap | 5.55B +79.4% |
| Revenue (ttm) | 254.31M +54.9% |
| Net Income | 172.63M |
| EPS | 8.05 |
| Shares Out | n/a |
| PE Ratio | 32.17 |
| Forward PE | 27.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21 |
| Open | 266.00 |
| Previous Close | 258.00 |
| Day's Range | 264.00 - 266.00 |
| 52-Week Range | 151.00 - 280.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteopor... [Read more]
News
Ligand initiated with an Overweight at Barclays
Barclays analyst Glen Santangelo initiated coverage of Ligand (LGND) with an Overweight rating and $345 price target The firm says Ligand is “differentiated” with a focus on aggregating biopharma roya...
Wainwright sees upside in Ligand after new CAR-T investment in AvenCell
H.C. Wainwright analyst Joseph Pantginis notes that this morning, Ligand (LGND) announced an up to $47M investment into AvenCell Therapeutics for development of its potentially differentiated CAR-T as...
Ligand enters financing agreement with AvenCell for up to $47M
Ligand (LGND) Pharmaceuticals announced that it has entered into a financing agreement with AvenCell Therapeutics for up to $47M. The investment will help advance AvenCell’s pipeline, including AVC-20...
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a ...
Ligand price target raised to $397 from $390 at Citi
Citi raised the firm’s price target on Ligand (LGND) to $397 from $390 and keeps a Buy rating on the shares. The firm cites the company’s acquisition of a royalty…
Ligand enters royalty agreement with Sydnexis for Ryjunea
Sydnexis announced an agreement with Ligand (LGND) Pharmaceuticals to sell its royalty rights associated with net sales of Ryjunea in Europe, the Middle East, and Africa. Under the terms of…
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced a...
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new...
Ligand acquires royalty, milestone interest in Santen’s Ryjunea from Sydnexis
Ligand (LGND) Pharmaceuticals announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical’s Ryjunea from Sydnexis for a $23M upfront payment. Under the terms of the agreeme...
Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million
Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to ...
Ligand Pharmaceuticals Transcript: 17th Annual Midwest IDEAS Conference
The company has rapidly scaled its royalty aggregation strategy, highlighted by the XOMA acquisition, which doubled its portfolio and is immediately accretive. Strong financials, a robust pipeline, and disciplined investment processes position it for significant near- and long-term growth.
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor confe...
Ligand Pharmaceuticals Slides: Corporate presentation
Ligand Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Ligand price target raised to $390 from $387 at Citi
Citi raised the firm’s price target on Ligand (LGND) to $390 from $387 and keeps a Buy rating on the shares.
Ligand initiated with an Outperform at Leerink
Leerink initiated coverage of Ligand (LGND) with an Outperform rating and $330 price target
Ligand price target raised to $345 from $340 at RBC Capital
RBC Capital analyst Douglas Miehm raised the firm’s price target on Ligand (LGND) to $345 from $340 and keeps an Outperform rating on the shares.
Ligand price target raised to $358 from $289 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Ligand (LGND) to $358 from $289 and keeps a Buy rating on the shares following the Q2 report. Ligand’s…
Ligand Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw revenue and EPS surge, driven by strong royalty growth and the transformative XOMA acquisition, which doubled the late-stage pipeline and added over 120 assets. The company raised $700 million in zero coupon convertible notes, reaffirmed robust guidance, and expects significant near-term catalysts across a diversified portfolio.
Ligand Pharmaceuticals Earnings release: Q2 2026
Ligand Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Ligand Pharmaceuticals Slides: Q2 2026
Ligand Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Ligand Pharmaceuticals Quarterly report: Q2 2026
Ligand Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Ligand reports Q2 adjusted EPS $2.37, consensus $1.97
Reports Q2 revenue $63.69M, consensus $61.26M. “Ligand (LGND) delivered another strong quarter, with royalty revenue growing 32% year-over-year and continued momentum from Filspari following its FSGS ...
Ligand narrows FY26 adjusted EPS view to $9.00-$9.50 from $8.50-$9.50
Consensus $9.20. Backs FY26 revenue view $270M-$310M, consensus $287.44M. The company said, “Ligand (LGND) is reaffirming its 2026 full-year revenue guidance and is raising the low end of its adjusted...
Ligand price target raised to $326 from $285 at Oppenheimer
Oppenheimer raised the firm’s price target on Ligand (LGND) to $326 from $285 and keeps an Outperform rating on the shares. The firm says its new model reflects the Xoma…
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 202...